HDM1005 injection or placebo

DRUG4 trials

Sponsors

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

ObesityObesity and OverweightOverweight and ObesityType 2 Diabetes

Phase 1

Phase Ia Clinical Study of HDM1005 Injection

CompletedNCT06640647

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Obesity and Overweight

Start: 2024-03-19End: 2024-09-26Updated: 2025-12-16

Phase Ib Clinical Study of HDM1005 Injection

CompletedNCT06637020

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Overweight and Obesity

Start: 2024-06-20End: 2025-02-14Updated: 2025-12-16

Phase 2

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

RecruitingNCT06886126

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Obesity

Start: 2025-02-07End: 2025-11-30Target: 240Updated: 2025-09-30

Phase 3

A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

RecruitingNCT07394114

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2026-02-24End: 2027-12-17Target: 240Updated: 2026-02-09

Related Papers

1034-OR: Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Diabetes2026-06-05

142-OR: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study

Diabetes2025-06-13